REG - Ovoca Bio PLC - Holding(s) in Company

Ovoca BioAnnouncement

23/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240123:nRSW5916Aa&default-theme=true

RNS Number : 5916A  Ovoca Bio PLC  23 January 2024

Ovoca Bio plc

 

("Ovoca" or the "Company")

 

 

Holding(s) in Company

 

Dublin, Ireland, January 23, 2024 - Ovoca Bio, a biopharmaceutical company
with a focus on women's health, received notification from Mr. Leonid Skoptsov
on 16 January 2024 that, as of 17 October 2023, he holds an interest in
10,002,078 ordinary shares of nominal value €0.125 each, which represents
12.26%* of the Company's issued share capital (excluding treasury shares). The
Company also received notification from Mr. Alexandr Mogutov on 16 January
2024 that, as of 17 October 2023, he no longer has a notifiable interest in
the Company's issued share capital (excluding treasury shares).

*This percentage shareholding is based on a share in issue figure of
81,563,806 ordinary shares of nominal value €0.125 each. The Company also
holds 6,895,000 ordinary shares in treasury, which do not carry voting rights.

End

 

For further information:

Ovoca Bio plc

Kirill Golovanov (Chief Executive)

Tel +353 1 661 9819

info@ovocabio.com (mailto:info@ovocabio.com)

 

Davy (Nominated Adviser, Euronext Growth Listing Sponsor and Broker)

Ivan Murphy / Daragh O'Reilly

Tel: +353 1 679 6363

 

 

 

About Ovoca Bio

Ovoca Bio is a European-based biopharmaceutical company with a focus on
women's health. The Company is currently developing Orenetide (BP-101), a
novel synthetic peptide administered through a nasal spray as a novel
treatment for women with hypoactive sexual desire disorder (HSDD), a condition
characterized by a distressing lack or loss of sexual desire affecting an
estimated ~4 million premenopausal women in the US alone.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  HOLFIFSRLRIVFIS